Stop transplanted insulin cells from dying

Researchers at Linköping University and Uppsala University in Sweden can show that accumulation of protein aggregatess, amyloid, in the transplanted cells may be causing their death. With the aid of their results, physicians can enhance survival of islets transplants and improve treatment of type 1 diabetes.

Focal hemorrhage in islet of Langerhans.
Focal hemorrhage in islet of Langerhans.

Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated. Until now it was not known why this insulin production ceases. The discovery now being published in The New England Journal of Medicine may change the course of diabetes research.

Transplant attempts have been carried out for more than 30 years. Hundreds of patients have had healthy insulin-producing islets of Langerhans recovered from the pancreas of donors. These transplants, which usually involve the injection of cell islets into the liver, normally go well, and the patients initially don’t have to take insulin. But within a year or two years the insulin production will cease from the transplanted cells.

“We have studied this in mice, but it has naturally been difficult to do so in humans. Now we have had an opportunity to examine such transplants in an individual with type 1 diabetes,” says Gunilla T. Westermark, assistant professor of cell biology at Linköping University.

In close to half of the cell islets examined, 43 percent, the researchers found lumps of amyloid. “We previously know that amyloid production is a symptom of stress that leads to cell death in type 2 diabetes. Perhaps the same thing happens in a transplant, when cells are exposed to great stress,” says Gunilla T. Westermark.

Interestingly, there were quite a few unaffected cell islets remaining in the liver. If we can prevent the production of amyloid at an early stage, these cells would be able to continue to produce insulin. One possible strategy is to create a drug; another would be to refine the methods used in transplants in order to reduce stress.

Image Courtesy: CDC/ Dr. Marshall Fox

16.09.2008

Read all latest stories

Related articles

Photo

News • Extracorporeal photopheresis

Study on ECP in heart transplant patients presents promising results

Results from a large European study reinforce the use of Extracorporeal photopheresis (ECP) in heart transplant patients as a treatment for heart transplant rejection and prevention of rejection.

Photo

News • Neuroscience, biomedical technology

Combining cell transplantation and gene therapy to enhance axonal outgrowth in the central nervous system

A study led by Dr. Ryosuke Tsuchimochi and Professor Jun Takahashi examined the effects of combining cell transplantation and gene therapy for axonal outgrowth in the central nervous system.

Photo

Article • Keratoplasty

Corneal transplantation surgery: AI for an eye

Many consider our eyes to be the windows to the soul. Yet the cornea, the panes of these windows, sometimes need significant repair. Friso Heslinga, PhD, created artificial intelligence models to…

Related products

Subscribe to Newsletter